• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

33
24
19
13
13

COUNTRY

13
6
6
6

CATEGORIES

  • 75
  • 10
  • 9
  • 8
  • 7
  • 5
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
SHOW ALL…

PRICE

51
79
99
116

PUBLISHED

3
4
8
116

PRODUCT TYPE

106
6
2
1
1

Search "Outcome Measures in Alzheimer's Disease" returned 116 results.

PRODUCT TITLE

Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted

GBI Research, the leading business intelligence provider, has released its latest research “Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely...

November 2011
FROM

Alzheimer's Disease – Pipeline Review, H1 2013

Global Markets Direct's, 'Alzheimer's Disease - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic development...

February 2013
FROM
Alzheimer's Disease - Pipeline Review, H2 2012 Alzheimer's Disease - Pipeline Review, H2 2012 - Product Thumbnail Image

Alzheimer's Disease - Pipeline Review, H2 2012

Alzheimer's Disease – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Alzheimer's Disease - Pipeline Review, H2 2012', provides an overview of the Alzheimer's Disease therapeutic pipeline....

August 2012
FROM

Alzheimer's Disease - Pipeline Review, H2 2013

'Alzheimer's Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic development for Alzheimer's Disease,...

August 2013
FROM
Global Clinical Trials for Alzheimer's Disease Global Clinical Trials for Alzheimer's Disease - Product Thumbnail Image

Global Clinical Trials for Alzheimer's Disease

Global Clinical Trials for Alzheimer's Disease is a handy one-stop reference for researchers and physicians planning and conducting global clinical trials in this area. This book addresses important...

November 2013
Targacept’s TC-5619 - The prospects for this fully-owned alpha-7 neuronal nicotinic receptor agonist Targacept’s TC-5619 - The prospects for this fully-owned alpha-7 neuronal nicotinic receptor agonist - Product Thumbnail Image

Targacept’s TC-5619 - The prospects for this fully-owned alpha-7 neuronal nicotinic receptor agonist

Earlier this year, Targacept reported that its phase II proof of concept study of TC-5619 in cognitive dysfunction in schizophrenia (CDS) met the pre-specified primary endpoint, while the trial in ADHD...

May 2011
FROM
Alzheimer's Disease - Pipeline Review, H1 2012 Alzheimer's Disease - Pipeline Review, H1 2012 - Product Thumbnail Image

Alzheimer's Disease - Pipeline Review, H1 2012

Alzheimer's Disease – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Alzheimer's Disease - Pipeline Review, H1 2012', provides an overview of the Alzheimer's Disease therapeutic pipeline....

February 2012
FROM

Alzheimer's Disease - Pipeline Review, H1 2014

Alzheimer's Disease - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Alzheimer's Disease - Pipeline Review, H1 2014’, provides an overview of the Alzheimer's Disease’s therapeutic pipeline. This...

February 2014
FROM
Neuroprotection - Drugs, Markets and Companies Neuroprotection - Drugs, Markets and Companies - Product Thumbnail Image

Neuroprotection - Drugs, Markets and Companies

This report describes the role of neuroprotection in acute disorders such as stroke and injuries of the nervous system as well as in chronic diseases such as neurodegenerative disorders because many...

October 2014
FROM

Alzheimer's Disease - Pipeline Review, Q4 2010

Alzheimer's Disease - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Alzheimer's Disease Pipeline Review, Q4 2010”, provides an overview of the Alzheimer's Disease therapeutic pipeline....

December 2010
FROM

Alzheimer's Disease - Pipeline Review, H2 2011

Alzheimer's Disease - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Alzheimer's Disease - Pipeline Review, H2 2011', provides an overview of the Alzheimer's Disease therapeutic pipeline....

September 2011
FROM

Biomarkers in Drug Discovery - Integration in Early Stage Promotes Use of Companion Diagnostics to Optimize Therapeutic Outcomes

GBI Research’s new report, “Biomarkers in Drug Discovery - Integration in Early Stage Promotes Use of Companion Diagnostics to Optimize Therapeutic Outcomes” provides information and analysis on the...

November 2012
FROM

Alzheimer's Disease - Pipeline Review, Q1 2011

Alzheimer's Disease - Pipeline Review, Q1 2011 Summary Global Markets Direct’s, 'Alzheimer's Disease - Pipeline Review, Q1 2011', provides an overview of the Alzheimer's Disease therapeutic pipeline....

February 2011
FROM

Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure

‘Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure’ provides insights into major drug failures during 2005–2010 The 20 drugs...

July 2011
FROM
Global Pharmaceutical & Biotechnology Outlook 2013: Global Pharma Global Pharmaceutical & Biotechnology Outlook 2013: Global Pharma - Product Thumbnail Image

Global Pharmaceutical & Biotechnology Outlook 2013: Global Pharma

Global Pharmaceutical & Biotechnology Outlook 2013: Global Pharma Over the next five years, we will witness surge in approval of new drugs that would deliver a major improvement in the standard of care...

January 2013
FROM
Biomarkers - Technologies, Markets and Companies Biomarkers - Technologies, Markets and Companies - Product Thumbnail Image

Biomarkers - Technologies, Markets and Companies

This report follows the broad definition of a biomarker as a characteristic that can be objectively measured and evaluated as an indicator of normal biological or pathogenic processes as well as pharmacological...

September 2014
FROM
2011 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities 2011 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities - Product Thumbnail Image

2011 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

This report includes details on 408 emerging medical technology companies that: have presented at a 2011 LSI Emerging Medical Technologies Spotlight meeting or have been identified by LSI's in-house...

December 2011
FROM
Emerging Medical Technologies Spotlight, A Report Of Investment & Partnering Opportunities, 2011 Emerging Medical Technologies Spotlight, A Report Of Investment & Partnering Opportunities, 2011 - Product Thumbnail Image

Emerging Medical Technologies Spotlight, A Report Of Investment & Partnering Opportunities, 2011

This report includes details on 408 emerging medical technology companies that: have presented at a 2011 LSI Emerging Medical Technologies Spotlight meeting or have been identified by LSI's in-house...

December 2011
FROM
Mild Cognitive Impairment - Pipeline Review, H1 2013 Mild Cognitive Impairment - Pipeline Review, H1 2013 - Product Thumbnail Image

Mild Cognitive Impairment - Pipeline Review, H1 2013

Mild Cognitive Impairment – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Mild Cognitive Impairment - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

April 2013
FROM
Mild Cognitive Impairment - Pipeline Review, H2 2012 Mild Cognitive Impairment - Pipeline Review, H2 2012 - Product Thumbnail Image

Mild Cognitive Impairment - Pipeline Review, H2 2012

Mild Cognitive Impairment – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Mild Cognitive Impairment - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline....

October 2012
FROM
Loading Indicator

Our Clients

Our clients' logos